What Digital Health companies can expect from the FDA in 2020

The FDA has announced their commitment to providing guidance on the following topics in the FY 2020.

FDA regulations do not provide a full, prescriptive manual for managing products in a regulated environment. For certain cases the FDA will elaborate by providing non-binding guidance documents with further details on how to interpret and apply regulations.

The FDA has announced their commitment to providing guidance on the following topics in the FY 2020.

The original full list separated into top and second tier priorities can be found HERE.

  • Recommendations for Dual 510(k) and Clinical Laboratory Improvement Amendments Waiver by Application Studies
  • 510(k) Third Party Review Program
  • Safer Technologies Program for Medical Devices
  • Process to Request a Review of FDA’s Decision Not to Issue Certain Export Certificates for Devices
  • Nonbinding Feedback After Certain Food and Drug Administration Inspections of Device Establishments
  • The Accreditation Scheme for Conformity Assessment (ASCA) Pilot Program
  • Recognition and Withdrawal of Voluntary Consensus Standards
  • Clinical Decision Support Software
  • Multiple Function Device Products: Policy and Considerations
  • Device-Specific Criteria Guidance(s) for Safety and Performance Based Pathway Implementation

Draft Guidance Topics

  • Content of Premarket Submissions for Management of Cybersecurity in Medical Devices
  • Distinguishing between Medical Device Servicing and Remanufacturing
  • Computer Software Assurance for Manufacturing, Operations, and Quality System Software
  • Postmarket Surveillance Under Section 522 of the Federal Food, Drug, and Cosmetic Act (revision)
  • Unique Device Identification: Policy on Enforcement of GUDID Submission Requirements for Certain Class I Devices
  • Pragmatic Generation of Validity Evidence for Patient-Reported Outcome Measures Used in Medical Device Submissions
  • Device-Specific Criteria Guidance(s) for Safety and Performance Based Pathway Implementation

If you have questions about how to apply these guidances within your company, contact us at info@enzyme.com.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.

Get more Enzyme in your inbox
Start with Enzyme today
info@enzyme.com or

What Digital Health companies can expect from the FDA in 2020

The FDA has announced their commitment to providing guidance on the following topics in the FY 2020.

FDA regulations do not provide a full, prescriptive manual for managing products in a regulated environment. For certain cases the FDA will elaborate by providing non-binding guidance documents with further details on how to interpret and apply regulations.

The FDA has announced their commitment to providing guidance on the following topics in the FY 2020.

The original full list separated into top and second tier priorities can be found HERE.

  • Recommendations for Dual 510(k) and Clinical Laboratory Improvement Amendments Waiver by Application Studies
  • 510(k) Third Party Review Program
  • Safer Technologies Program for Medical Devices
  • Process to Request a Review of FDA’s Decision Not to Issue Certain Export Certificates for Devices
  • Nonbinding Feedback After Certain Food and Drug Administration Inspections of Device Establishments
  • The Accreditation Scheme for Conformity Assessment (ASCA) Pilot Program
  • Recognition and Withdrawal of Voluntary Consensus Standards
  • Clinical Decision Support Software
  • Multiple Function Device Products: Policy and Considerations
  • Device-Specific Criteria Guidance(s) for Safety and Performance Based Pathway Implementation

Draft Guidance Topics

  • Content of Premarket Submissions for Management of Cybersecurity in Medical Devices
  • Distinguishing between Medical Device Servicing and Remanufacturing
  • Computer Software Assurance for Manufacturing, Operations, and Quality System Software
  • Postmarket Surveillance Under Section 522 of the Federal Food, Drug, and Cosmetic Act (revision)
  • Unique Device Identification: Policy on Enforcement of GUDID Submission Requirements for Certain Class I Devices
  • Pragmatic Generation of Validity Evidence for Patient-Reported Outcome Measures Used in Medical Device Submissions
  • Device-Specific Criteria Guidance(s) for Safety and Performance Based Pathway Implementation

If you have questions about how to apply these guidances within your company, contact us at info@enzyme.com.

Get more of Enzyme

Sign up for the latest updates in your inbox

Enzyme Blog

Automating life science regulatory and compliance

Making MDSAP Work for You
Jul 1, 2020
9
min read
The Single Device Audit: Great Hopes Still Unfulfilled
Jun 24, 2020
8
min read
Management System Status for ISO 13485 Complicates FDA Adoption
Jun 18, 2020
9
min read
Suspended Animation; U.S. LDT Regulation Behind EU
Jun 12, 2020
9
min read
Leftovers: Top Five Unfinished FDA Draft Guidances from 2019
Jun 7, 2020
8
min read
ISO 13485 and Part 820: Delays and Opportunities
May 29, 2020
8
min read
Best Practices for Handling Customer Complaints Post-Market
Mar 23, 2020
5
min read
Enzyme Offers Support for Teams Dealing with COVID-19
Mar 19, 2020
5
min read
How the Medical Device Sector Can Support Innovation Methods for Developing Digital Health Products
Mar 16, 2020
7
min read
A Guide to Navigating FDA Device Risk Classifications for New Products
Feb 21, 2020
5
min read
What Digital Health companies can expect from the FDA in 2020
Oct 17, 2019
2
min read
Expert Interview: Clinical Trial Planning for Startups with Boulder Clinical Science
Oct 15, 2019
5
min read
2019 RAPS Regulatory Convergence #2019RAPS
Sep 19, 2019
1
min read
Farewell, Dr. Gottlieb, you will be missed
Mar 7, 2019
3
min read
Creating A Culture Of Quality
Feb 19, 2019
3
min read
Our top conference picks for SaMD companies
Jan 25, 2019
3
min read
FDA Pre-Cert v1.0 Explained: 2019 and the Promises of Years to Come
Jan 9, 2019
7
min read
Ready to level up? Inquire about certification.
info@enzyme.com or

Ready to do more?